Latest Observability News

Locksley Resources has identified the Beefeater Shear, a significant new structural corridor at its Mojave Project, promising to expand high-grade antimony targets. Detailed underground mapping at the Desert Antimony Mine reveals fresh opportunities for resource growth.

Golden Dragon Mining’s initial drilling at Coodardy within the Cue Gold Project has revealed continuous high-grade gold mineralisation close to surface, boosting prospects for open pit development.

Apiam Animal Health’s acquisition scheme by Adamantem Capital has been legally approved, leading to the suspension of its shares on the ASX. Key dates for dividend payments and scheme implementation are now set.

Neuren Pharmaceuticals has dosed the first patient in its groundbreaking Phase 3 trial of NNZ-2591 for Phelan-McDermid syndrome, a rare genetic disorder with no approved therapies. The trial marks a significant step forward for the PMS community and rare disease drug development.

Manuka Resources’ subsidiary Trans-Tasman Resources has received a draft decision proposing to decline consent for its Taranaki VTM iron sands project, challenging the company’s plans to develop a critical minerals supply in New Zealand.

Elders Limited has announced René Dedoncker as its next CEO, set to begin in October 2026, with current CEO Mark Allison staying on through a transition period. Dedoncker brings two decades of agribusiness leadership experience from Fonterra and Mars Corporation.

Koonenberry Gold has reported promising Phase II drilling results at its Sunnyside Prospect, extending gold mineralisation to 415 metres vertical depth and revealing high-grade zones at depth. The company’s ongoing exploration efforts continue to highlight the potential for a significant gold system in New South Wales.

Australian Critical Minerals Ltd has updated its Flint Gold-Silver Project presentation, confirming drill readiness with permits and funding secured for an initial diamond drilling program in Peru’s prolific epithermal belt.

Neuren Pharmaceuticals has received detailed feedback from the US FDA on its clinical development plans for NNZ-2591 targeting hypoxic ischemic encephalopathy and Pitt Hopkins syndrome, paving a clearer path forward despite some delays.

Evolution Trustees has appointed LDR Capital as the new manager of Elanor Commercial Property Fund following the termination of previous management agreements with Elanor Asset Services.

Transurban Group reveals modest investor uptake in its latest Distribution Reinvestment Plan, with new securities priced at $13.89 and set for issuance in February.

Patagonia Lithium has advanced drilling at its Formentera lithium project in Argentina to 308 metres, revealing encouraging porosity and brine characteristics that suggest strong lithium potential. Six successful packer tests indicate increasing brine concentration and flow rates, with further drilling planned to deepen the resource understanding.